Finn Brooks: Hey, okay — I have to confess something embarrassing: I thought Ozempic and Wegovy were basically the same drug with different branding, and I was completely wrong in a way that turns out to actually matter.
Clara Bennett: They are the same molecule — semaglutide — but you're right that the distinction matters enormously here. Ozempic is indicated for type 2 diabetes. Wegovy is the same ingredient, FDA-approved in 2021, for chronic weight management. Different populations, very different clinical support structures around them.
Finn Brooks: And THAT is the crack in the dam, right? Because the moment Wegovy opens the door to weight loss patients, the poison control call volume — through America's Poison Centers, which is tracking all 55 centers nationally — nearly doubled that same year.
Clara Bennett: Nearly 3,000 calls just in the first eleven months of 2023. And then — in just the first four months of 2025, 3,633 cases. The trajectory is not flattening.
Finn Brooks: Which — hang on — means three-plus years of public awareness campaigns, labeling updates, all of it... and we're going the wrong direction?
Clara Bennett: That's the uncomfortable part. And Dr. Kait Brown at America's Poison Centers says it clearly: these are dosing errors. Not misuse, not diversion. People are just getting the dose wrong — in ways that shouldn't be possible if the onboarding infrastructure was working.
Finn Brooks: So it's like — imagine you handed someone a nail gun with no training and they drove a nail through their hand. That's a tragedy, but it's also completely predictable. The tool didn't fail.
Clara Bennett: That's the intuition, yes. The drug is the same drug. What collapsed was the context around who's using it and whether anyone taught them how.
Finn Brooks: And the tool's complexity is — wait, this is the stat that stands out — 94% of America's Poison Centers semaglutide calls? Semaglutide alone. No other drugs involved. Which means we can't even tell the story where it's a drug-interaction problem or accidental polypharmacy or whatever. The hazard is baked into the drug's own architecture.
Clara Bennett: That's a real number. And the University of New Mexico Hospital data sharpens it further — 78% of their 2023 semaglutide calls were incorrect dosing. Some of those were ten-fold overdoses. Not double. Ten times the intended dose.
Finn Brooks: Ten-fold. That's not a rounding error.
Clara Bennett: It's not. And — now, this is the part I want to be precise about — that doesn't tell us the patient was negligent. It tells us the dosing architecture created the conditions. Weekly injections instead of daily, the mechanical differences between the Ozempic pen and the Wegovy injector, compounded semaglutide that may not even replicate the same delivery curve. These are not equivalent tools with a common-sense dose.
Finn Brooks: Okay but here's what actually broke my brain on this — the team that surfaced the whole pattern publicly? Jordan Miller. Undergraduate. UT San Antonio. Not an FDA pharmacovigilance team, not a manufacturer's safety desk. An undergrad.
Clara Bennett: Mentored by David Han — Romo Endowed Professor in UT San Antonio's Statistics and Data Science department — and co-authored with Robert S. Miller and Shawn Varney from the South Texas Poison Center. So the institutional scaffolding was there. But your question stands — why did that team see it and not, say, MedWatch?
Finn Brooks: Right — and I'm not saying the FDA was asleep, I mean — actually, no, maybe I am saying that a little.
Clara Bennett: The more defensible version is that passive reporting systems like MedWatch capture what clinicians choose to submit. Poison center data is active — every call gets logged. That's a structural difference in what each system can even see.
Finn Brooks: So the data existed. Someone just had to go look at it. And it took an undergraduate to do that.
Clara Bennett: But that data visibility point — that's actually where I want to push, because there's something underneath it that we're skating past. Before 2021, nationally, GLP-1 receptor agonist calls were sitting between one thousand and fifteen hundred annually. After Wegovy's approval, calls nearly doubled by mid-2021. Same molecule. The FDA didn't approve a new drug — it approved a new patient population. And that population had no endocrinologist, no ongoing blood work, no in-person follow-up built in.
Finn Brooks: Okay but — wait — insulin is objectively more lethal in overdose than semaglutide, right? Like, you get a wrong insulin dose and you can die within hours. We did not see this disaster with insulin when telehealth expanded.
Clara Bennett: Insulin is terrifying in overdose, that's true. But insulin patients — even telehealth ones — are monitoring blood glucose constantly. The feedback loop is immediate and visceral. You feel a hypoglycemic episode. Semaglutide's harm profile is slower, subtler. A weekly injection means someone can stack doses across days before anything feels wrong.
Finn Brooks: Hm. I want to believe that but — I mean, is that the FDA's failure specifically, or is that just... telehealth as a business model shipping drugs without the clinical infrastructure attached?
Clara Bennett: That's the real fault line. And I don't think those are separable. The FDA's 2021 Wegovy approval didn't mandate any delivery infrastructure for weight management. Diabetes approvals grew alongside specialty care networks. The FDA drew the line at the label, not the pathway to the patient.
Finn Brooks: No, I don't fully buy that.
Clara Bennett: The Connecticut Poison Control Center reported a tripling of GLP-1 calls over a two-year window. Not doubling — tripling. That's not a telehealth startup problem localized to one platform. That's every state, every delivery mechanism, same curve. Which — actually, picture the scenario. A 34-year-old gets a Wegovy prescription through a fifteen-minute telehealth visit. No pen demonstration. No one explains that weekly dosing means one injection covers seven days, not one. That confusion alone gets you ten-fold overdoses.
Finn Brooks: Connecticut tripling — okay, that lands. That's not anecdote. But I'd still argue the FDA set the table and telehealth sat down and made a mess of it. The approval created the opening; the business model poured through it.
Clara Bennett: And honestly — neither of us is walking away from this without conceding something. But the part that makes all of this harder? We haven't even touched compounded semaglutide yet, and the equity dynamics around who gets cut off if oversight tightens. That's coming, and it makes this argument look simple by comparison.
Finn Brooks: Okay, compounded semaglutide — I'll just say it flat out: yeah, I concede that one. Variable concentrations, nonstandard packaging, none of the Novo Nordisk quality controls. America's Poison Centers and the South Texas Poison Center both flag it as its own distinct risk category, not just 'more of the same problem.' That's measurably more dangerous. I'll take that.
Clara Bennett: Noted. But here's where I won't move — tightening compounding oversight without touching brand-name pricing is just access restriction wearing a safety badge.
Finn Brooks: Right, and THAT is the trap, because — wait, actually this is the part that keeps me up — if you squeeze compounded semaglutide out of the market, lower-income patients don't suddenly get Wegovy. They get something even less regulated, or nothing. The affordability gap doesn't close.
Clara Bennett: And Novo Nordisk has almost no market incentive to lower Ozempic or Wegovy prices while demand is this inelastic. ScienceDaily reporting Jordan Miller's findings brought this into public view — but notably, that happened because independent academics connected the dots, not manufacturers, not regulators.
Finn Brooks: So the equity trap is basically... self-sealing?
Clara Bennett: In practice, yes. The patients most likely to use compounded semaglutide are cost-sensitive — that's the whole point of it existing. Tighter oversight without a pricing fix doesn't improve their safety. It removes their option.
Finn Brooks: I mean — okay, I love the regulatory architecture argument, I do, but fixing the FDA's approval framework doesn't help the person who can't afford $1,300 a month right now. Those are two different clocks running at two different speeds.
Clara Bennett: And that's the gap we're not closing today. You want to fix the market; I want the regulatory architecture built before the next molecule gets this big. Both things can be true and still leave a real distance between us.
Finn Brooks: Wait, but that's the thing — at the start I thought this was a branding mix-up, Ozempic versus Wegovy, same drug different box. And now we're at 3,633 poison center cases in four months of 2025, three years past approval, education campaigns running, and the number is still climbing. That's not a labeling fix. That's — I mean, the drug got approved for the masses and the clinical support got built for a specialty clinic. Those were never going to converge.
Clara Bennett: Public health officials are still calling for better patient education and clearer labeling — measures that weren't built into the original Wegovy approval framework. Which is a real answer. It's just not scaled to the problem in front of us. And I don't know that it ever will be, given how the weight-loss market is structured.
Finn Brooks: Yeah. We approved a drug for everyone and built the support system for people with endocrinologists.
Clara Bennett: That's where I'll stay uncomfortable. Thanks for pushing on it.
